Cover Image
市場調查報告書

甲一型抗胰蛋白酵素缺乏症:開發中產品分析

Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 203700
出版日期 內容資訊 英文 83 Pages
訂單完成後即時交付
價格
Back to Top
甲一型抗胰蛋白酵素缺乏症:開發中產品分析 Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2017
出版日期: 2017年08月22日 內容資訊: 英文 83 Pages
簡介

甲一型抗胰蛋白酵素缺乏症 (AAT缺乏症)是遺傳性症狀,是由於欠缺保護肺臟之蛋白質甲一型抗胰蛋白酵素 (AAT) 所造成。主要的症狀有呼吸困難·喘鳴聲音和肺感染疾病,心跳,體重減少,視力異常等。此外主要發病因素有抽煙和暴露於塵埃,化學煙霧,感染疾病等。

甲一型抗胰蛋白酵素缺乏症 (AAT缺乏症)是遺傳性症狀,是由於欠缺保護肺臟之蛋白質甲一型抗胰蛋白酵素 (AAT) 所造成。主要的症狀有呼吸困難·喘鳴聲音和肺感染疾病,心跳,體重減少,視力異常等。此外主要發病因素有抽煙和暴露於塵埃,化學煙霧,感染疾病等。

本報告提供全球各國治療甲一型抗胰蛋白酵素缺乏症所用的開發中產品開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要 (產品概要,功能機制,研究開發 (R&D)的發展情形),最新的產業趨勢等調查。

簡介

  • 分析範圍

甲一型抗胰蛋白酵素缺乏症概要

治療藥的開發

  • 甲一型抗胰蛋白酵素缺乏症開發中產品:概要

各企業開發中的甲一型抗胰蛋白酵素缺乏症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

甲一型抗胰蛋白酵素缺乏症治療藥:開發中的產品的一覽 (各企業)

甲一型抗胰蛋白酵素缺乏症開發治療藥的企業

  • Adverum Biotechnologies, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Applied Genetic Technologies Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • Carolus Therapeutics, Inc.
  • Cevec Pharmaceuticals GmbH
  • Dicerna Pharmaceuticals, Inc.
  • Digna Biotech, S.L.
  • Editas Medicine, Inc.
  • Grifols, S.A.
  • Inhibrx
  • Intellia Therapeutics, Inc.
  • International Stem Cell Corporation
  • Ionis Pharmaceuticals, Inc.
  • Kamada Ltd.
  • Polyphor Ltd.
  • ProMetic Life Sciences Inc.
  • rEVO Biologics, Inc.
  • Sangamo BioSciences, Inc.

甲一型抗胰蛋白酵素缺乏症:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

甲一型抗胰蛋白酵素缺乏症治療藥:開發暫停的產品

甲一型抗胰蛋白酵素缺乏症治療藥:開發中止的產品

甲一型抗胰蛋白酵素缺乏症相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9637IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2017, provides an overview of the Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline landscape.

Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that protects the lungs. Symptoms include shortness of breath and wheezing, lung infections, rapid heartbeat, weight loss and vision problems. Predisposing factors include smoking, exposure to dust, chemical fumes and infections.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Alpha- Antitrypsin Deficiency (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Alpha- Antitrypsin Deficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 2, 9 and 5 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alpha- Antitrypsin Deficiency (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Alpha- Antitrypsin Deficiency (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alpha- Antitrypsin Deficiency (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alpha- Antitrypsin Deficiency (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alpha- Antitrypsin Deficiency (Genetic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alpha- Antitrypsin Deficiency (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Alpha- Antitrypsin Deficiency - Overview
    • Alpha- Antitrypsin Deficiency - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Alpha- Antitrypsin Deficiency - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Alpha- Antitrypsin Deficiency - Companies Involved in Therapeutics Development
    • Adverum Biotechnologies Inc
    • Alnylam Pharmaceuticals Inc
    • Applied Genetic Technologies Corp
    • Arrowhead Pharmaceuticals Inc
    • Carolus Therapeutics Inc
    • Cevec Pharmaceuticals GmbH
    • Editas Medicine Inc
    • Grifols SA
    • Inhibrx LP
    • Intellia Therapeutics Inc
    • International Stem Cell Corp
    • Kamada Ltd
    • OncBioMune Pharmaceuticals Inc
    • Polyphor Ltd
    • ProMetic Life Sciences Inc
    • rEVO Biologics Inc
    • Z Factor Ltd
  • Alpha- Antitrypsin Deficiency - Drug Profiles
    • ADVM-043 - Drug Profile
    • AGTC-0106 - Drug Profile
    • ALN-AAT - Drug Profile
    • ALNAAT-02 - Drug Profile
    • alpha-1 proteinase inhibitor (human) - Drug Profile
    • alpha-1 proteinase inhibitor (human) second generation - Drug Profile
    • alpha-1 proteinase inhibitor (recombinant) - Drug Profile
    • ARC-AAT - Drug Profile
    • ARO-AAT - Drug Profile
    • CT-2009 - Drug Profile
    • Drug for Chronic Obstructive Pulmonary Disease and Alpha-1 Antitrypsin Deficiency - Drug Profile
    • Gene Therapy for Alpha-1 Antitrypsin Deficiency - Drug Profile
    • Oligonucleotides to Activate Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency - Drug Profile
    • Oligonucleotides to Inhibit Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency - Drug Profile
    • POL-6014 - Drug Profile
    • rAAV2-CB-hAAT - Drug Profile
    • Recombinant Human Alpha-1 Antitrypsin - Drug Profile
    • Recombinant Human Alpha-1 Antitrypsin Replacement for Alpha-Antitrypsin Deficiency - Drug Profile
    • Recombinant Protein for Alpha-1 Antitrypsin Deficiency - Drug Profile
    • Small Molecules for Alpha-1 Antitrypsin Deficiency - Drug Profile
    • Small Molecules to Activate SERPINA1 for Alpha-1 Antitrypsin Deficiency - Drug Profile
    • Small Molecules to Inhibit Alpha-1 Antitrypsin Polymerization for Alpha-1 Antitrypsin Deficiency - Drug Profile
    • Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis - Drug Profile
  • Alpha- Antitrypsin Deficiency - Dormant Projects
  • Alpha- Antitrypsin Deficiency - Discontinued Products
  • Alpha- Antitrypsin Deficiency - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Alpha- Antitrypsin Deficiency, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Alpha- Antitrypsin Deficiency - Pipeline by Adverum Biotechnologies Inc, H2 2017
  • Alpha- Antitrypsin Deficiency - Pipeline by Alnylam Pharmaceuticals Inc, H2 2017
  • Alpha- Antitrypsin Deficiency - Pipeline by Applied Genetic Technologies Corp, H2 2017
  • Alpha- Antitrypsin Deficiency - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2017
  • Alpha- Antitrypsin Deficiency - Pipeline by Carolus Therapeutics Inc, H2 2017
  • Alpha- Antitrypsin Deficiency - Pipeline by Cevec Pharmaceuticals GmbH, H2 2017
  • Alpha- Antitrypsin Deficiency - Pipeline by Editas Medicine Inc, H2 2017
  • Alpha- Antitrypsin Deficiency - Pipeline by Grifols SA, H2 2017
  • Alpha- Antitrypsin Deficiency - Pipeline by Inhibrx LP, H2 2017
  • Alpha- Antitrypsin Deficiency - Pipeline by Intellia Therapeutics Inc, H2 2017
  • Alpha- Antitrypsin Deficiency - Pipeline by International Stem Cell Corp, H2 2017
  • Alpha- Antitrypsin Deficiency - Pipeline by Kamada Ltd, H2 2017
  • Alpha- Antitrypsin Deficiency - Pipeline by OncBioMune Pharmaceuticals Inc, H2 2017
  • Alpha- Antitrypsin Deficiency - Pipeline by Polyphor Ltd, H2 2017
  • Alpha- Antitrypsin Deficiency - Pipeline by ProMetic Life Sciences Inc, H2 2017
  • Alpha- Antitrypsin Deficiency - Pipeline by rEVO Biologics Inc, H2 2017
  • Alpha- Antitrypsin Deficiency - Pipeline by Z Factor Ltd, H2 2017
  • Alpha- Antitrypsin Deficiency - Dormant Projects, H2 2017
  • Alpha- Antitrypsin Deficiency - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Alpha- Antitrypsin Deficiency, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top